Genomtec goes public on NewConnect on March 17th

The Warsaw Stock Exchange has just announced that March 17 this year to be the first day of listing Genomtec shares on the NewConnect trading floor. The company deals with medical technology, specializing in isothermal amplification of nucleic acids, applicable both in clinical diagnostics in the place of patient care – POCT, and rapid genetic testing. The company's flagship solution is the innovative, mobile Genomtec ID diagnostic system – repeatedly awarded in international technology competitions.

“The long-awaited debut is ahead of us. We carried out the verification of our company very efficiently before the Stock Exchange. We are glad that the development model we have chosen using the stock exchange may enter the next stage, and Genomtec will be a company listed on the public market. Genomtec's goal is to revolutionize genetic diagnostics in the world. Our international team has the necessary knowledge, experience, and skills to do this,” Miron Tokarski, founder and president of Genomtec, said.

Last year, Genomtec completed the initial public offering of series J shares. The offer met with great interest from investors. They declared interest in shares worth over PLN 50 million, which is several times the value of the issue. The company successfully placed all offered shares at a maximum price of PLN 11 per share and raised over PLN 8 million from the issue for the implementation of the development strategy.

(WBJ)